PD 166285 dihydrochloride

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Background References

1. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors
   F Pareja, AH Brandes, T Basili, P Selenica, FC Geyer, D Fan, A Da Cruz Pa, R Kumar, DN Brown, R Gularte-Mé, B Alemar, R Bi, RS Lim, I de Bruijn, S Fujisawa, R Gardner, E Feng, A Li, EM da Silva, JR Lozada, P Blecua, L Cohen-Goul, AA Jungbluth, EA Rakha, IO Ellis, MIA Edelweiss, J Palazzo, L Norton, T Hollmann, M Edelweiss, BP Rubin, B Weigelt, JS Reis-Filho
   Nat Commun, 2018;9(1):3533.
2. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
   Panek et al.
   J.Pharmacol.Exp.Ther., 1997;283:1433
3. Radiosensitization of p53 mutant cells by PD0166285, a novel G₂ checkpoint abrogator.
   Wang et al.
   Cancer Res., 2001;61:8211
4. Cell cycle regulation by the Wee1 inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
   Hashimoto et al.
   BMC Cancer, 2006;6:292

Product Datasheets